SSShayda A. Swann

Shayda A. Swann

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shayda A. Swann has a total of 58 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Self‐reported HIV viral load is reliable and not affected by adverse lived experiences of women living with HIV in British Columbia

    by Tetiana Povshedna, Shayda A. Swann, Marcela A. P. Silva, Shelly Tognazzini, Melanie Lee, Elizabeth M. King, Zoë Osborne, Angela Kaida, Melanie C. M. Murray, Hélène C. F. Côté, et al.

    Introduction: HIV viral load (VL) is a key predictor of long‐term health for women living with HIV. Here, we investigate how HIV VL self‐reported by women living with HIV enrolled in the British Columbia CARMA‐CHIWOS Collaboration Study relates to clinically measured HIV VL. Three HIV‐related stigma scales and associations with selected socio‐demographic characteristics, such as lifetime history of homelessness, history of substance use, ethnicity, and knowledge about ‘Undetectable = Untransmittable’, were also examined.Methods: For 219 women enrolled between December 2020 and August 2023, self‐reported HIV VL status (classified as undetectable ≤40 copies/mL or detectable >40 copies/mL) was compared with HIV VL obtained from chart review closest to, but before the date of self‐report (SR). Sensitivity, specificity, predictive values, and likelihood ratios were calculated for the study sample overall and for socio‐demographically defined subgroups. Concordance between self‐reported HIV VL and (CC) clinical chart‐derived values was examined by Cohen's kappa. Three HIV‐related stigma scores were compared between women stratified by the concordance of their self‐reported and chart review‐based HIV VL.Results: Ninety‐five percent (208/219) of women were able to estimate their most recent HIV VL via self‐report, and among them, 96% (200/208) were on antiretroviral therapy, 50% reported a history of homelessness, and 30% reported current substance use. Overall, the self‐reported HIV VL was correctly estimated by 189 out of 219, and showed high overall concordance (86%) and moderate agreement (Cohen's kappa = 0.55) with HIV VL values derived from CCs. Correctly self‐reported undetectable HIV VL showed high sensitivity (97.2%) and positive likelihood ratio (1.92), low negative likelihood ratio (0.06), moderate specificity (50%), and performed similarly across socio‐demographic subgroups. HIV stigma scores did not differ between women who estimated their HIV VL correctly versus incorrectly. Of note, knowledge about ‘Undetectable = Untransmittable’ was lower (40%) among women who were not able to estimate their most recent VL than among those who did (74%).Conclusions: Our findings confirm previous reports of high awareness of HIV VL by women in British Columbia, Canada, despite a high prevalence of adverse socio‐demographic experiences in this cohort. Our data further suggest that despite highly stigmatized life experiences, women living with HIV in British Columbia have a strong awareness of their VL status.


  • Open Access

    Associations of Early Prolonged Secondary Amenorrhea in Women With and Without HIV

    by Shayda A Swann, Elizabeth M King, Davi Pang, Marcela A P Silva, Amber R Campbell, Jerilynn C Prior, Mona Loutfy, Angela Kaida, Hélène C F Côté, Melanie C M Murray

    Background: The menstrual cycle is a critical indicator of women's health. Early prolonged secondary amenorrhea increases risks for morbidity and mortality. Menstrual cycle research in women with HIV is inconsistent and often lacks an adequate comparison sample. We aimed to determine whether women with HIV have a higher lifetime prevalence of amenorrhea and whether this is independently associated with HIV and/or other biopsychosocial variables. Methods: With data from 2 established HIV cohorts, participants assigned female at birth were eligible if aged ≥16 years, not pregnant/lactating, and without anorexia/bulimia nervosa history. Amenorrhea was defined by self-reported history of (1) no menstrual flow for ≥12 months postmenarche not due to pregnancy/lactation, medications, or surgery or (2) early menopause or premature ovarian insufficiency. Multivariable logistic regression models explored biopsychosocial covariates of amenorrhea. Results: Overall, 317 women with HIV (median age, 47.5 years [IQR, 39.2–56.4]) and 420 women without HIV (46.2 [32.6–57.2]) were included. Lifetime amenorrhea was significantly more prevalent among women with HIV than women without HIV (24.0% vs 13.3%). In the multivariable analysis, independent covariates of amenorrhea included HIV (adjusted odds ratio, 1.70 [95% CI, 1.10–2.64]), older age (1.01 [1.00–1.04]), White ethnicity (1.92 [1.24–3.03]), substance use history (6.41 [3.75–11.1]), and current food insecurity (2.03 [1.13–3.61]). Conclusions: Nearly one-quarter of women with HIV have experienced amenorrhea, and this is associated with modifiable risk factors, including substance use and food insecurity. Care providers should regularly assess women's menstrual health and advocate for actionable sociostructural change to mitigate risks.


  • Longitudinal Assessment of Bone Mineral Density in Women Living With and Without HIV Across Reproductive Phases

    by Shayda A. Swann, Elizabeth M. King, Jerilynn C. Prior, Claudie Berger, Ulrike Mayer, Neora Pick, Amber R. Campbell, Hélène C. F. Côté, Melanie C. M. Murray

    Background: Women living with HIV commonly experience low areal bone mineral density (BMD), but whether this is affected by low ovarian hormonal states (prolonged amenorrhea or menopause) is unknown. We compared rates of BMD loss between women living with HIV and HIV-negative control women and investigated its association with low ovarian hormonal states. Setting: Women living with HIV were enrolled from Vancouver Canada and controls from 9 Canadian sites. Methods: This longitudinal analysis included age-matched women living with HIV in the Children and Women: AntiRetrovirals and Markers of Aging cohort and controls in the population-based Canadian Multicentre Osteoporosis Study. Rate of change/year in BMD at the total hip and lumbar spine (L1–L4) between 3 and 5 years was compared between groups, adjusting for sociodemographic and clinical variables. Results: Ninety-two women living with HIV (median [interquartile range] age: 49.5 [41.6–54.1] years and body mass index: 24.1 [20.7–30.8] kg/m2) and 278 controls (age: 49.0 [43.0–55.0] years and body mass index: 25.8 [22.9–30.6] kg/m2) were included. Total hip BMD loss was associated with HIV (β: −0.003 [95% CI: −0.006 to −0.0001] g/cm2/yr), menopause (β: −0.007 [−0.01 to −0.005] g/cm2/yr), and smoking (β: −0.003 [−0.006 to −0.0002] g/cm2/yr); BMD gain was linked with higher body mass index (β: 0.0002 [0.0007–0.0004] g/cm2/yr). Menopause was associated with losing L1–L4 BMD (β: −0.01 [−0.01 to −0.006] g/cm2/yr). Amenorrhea was not associated with BMD loss. Conclusions: HIV and menopause negatively influenced total hip BMD. These data suggest women living with HIV require hip BMD monitoring as they age.


  • Open Access

    Age at Natural Menopause in Women Living with HIV: A Cross-Sectional Study Comparing Self-Reported and Biochemical Data

    by Shayda A. Swann, Elizabeth M. King, Shelly Tognazzini, Amber R. Campbell, Sofia L. A. Levy, Neora Pick, Jerilynn C. Prior, Chelsea Elwood, Mona Loutfy, Valerie Nicholson, et al.

    Early menopause ( 0.05). Overall, HIV status per se was not statistically associated with an earlier age at menopause, emphasizing the importance of comparing socio-demographically similar women in reproductive health and HIV research.


  • Vitamin D intakes among women living with and without HIV in Canada

    by Elizabeth M. King, Shayda A. Swann, Jerilynn C. Prior, Claudie Berger, Ulrike Mayer, Neora Pick, Amber R. Campbell, Hélène C. F. Côté, Melanie C. M. Murray, the CIHR team on Cellular Aging and HIV Comorbidities in Women and Children (CARMA)

    Background: Patterns of vitamin D intake are relatively unexplored among women living with HIV, despite its importance for women's health. We compared vitamin D dietary and supplement intakes in women with HIV and population-based national controls and investigated barriers to intake.Methods: In this case-control study, women with HIV in the Children and Women: AntiRetrovirals and Markers of Aging (CARMA) cohort were matched with Canadian Multicentre Osteoporosis Study (CaMos) controls. Participants were queried for vitamin D in dairy consumption, supplementation/dosage, and sociodemographic variables. We assessed barriers to supplementation and factors associated with dietary intake by regression modelling.Results: Ninety-five women living with HIV were age-matched to 284 controls. Women with HIV had lower income and bone mineral density and were more likely to smoke, take multiple medications and be non-white. Vitamin D dietary intake was lower in women living with HIV versus controls [0.76 vs. 1.79 mu g/day; adjusted odds ratio (aOR) for greater than or equal to median intake 0.29 (0.12-0.61), p = 0.002], but any supplementation was higher [62.2% vs. 44.7%; aOR = 3.44 (95% CI: 1.16-11.00), p = 0.03]. Total vitamin D intake was similar between groups. Smoking was associated with no supplementation; non-white ethnicity and low income were related to lower dietary intake.Conclusions: Women living with HIV showed lower dietary vitamin D intake but higher supplementation rates, suggesting that care providers are promoting supplementation. Women living with HIV who smoke, have low incomes and are non-white may particularly benefit from targeted efforts to improve vitamin D intake.


  • Markers of ovarian reserve in women living with HIV: A systematic review

    by Elizabeth M. King, Shayda A. Swann, Melanie C. M. Murray

    Background: Anti‐Mullerian hormone (AMH) levels indicate ovarian reserve and are predictive of reproductive aging. Studies evaluating AMH levels in women with HIV have produced conflicting results, and reasons for inter‐study differences have not been assessed. To understand reproductive aging in HIV, we conducted a systematic review of ovarian reserve among women with HIV.Methods: We searched Ovid MEDLINE, Ovid EMBASE, and CAB Direct for studies including AMH in reproductive‐aged women with HIV. Two reviewers used the Newcastle–Ottawa scale to assess the quality of extracted data.Results: Of the 315 reports screened, ten met the inclusion criteria. Studies were conducted across seven countries and included 3673 women with HIV and 2342 HIV‐negative women in the comparison group. Ethnic distribution, combination antiretroviral therapy coverage, and viral load suppression varied considerably across studies. Nine of the ten reviewed studies reported lower unadjusted AMH levels in women with HIV than in those without HIV; however, in studies that adjusted for confounders (n = 4), only two showed an association between HIV and AMH. Low CD4 count and high viral load correlated with low AMH in the two largest studies. Other studies found that opioid use and elevated inflammatory markers were associated with low AMH. Study quality varied considerably, and many were of low quality (n = 6).Conclusion: Current evidence is inconclusive about the relationship between HIV and AMH, although studies suggest a trend toward lower AMH among women with HIV. Future studies that adjust for HIV‐related factors, inflammatory markers, and substance use are needed in the era of contemporary HIV care to confirm the association between HIV and reduced ovarian reserve and establish its underlying cause.


  • Stressing the need for validated measures of cortisol in HIV research: A scoping review

    by Shayda A. Swann, Elizabeth M. King, Hélène C. F. Côté, Melanie C. M. Murray

    Objectives People living with HIV experience numerous endocrine abnormalities and psychosocial stressors. However, interactions between HIV, cortisol levels, and health outcomes have not been well described among people living with HIV on effective therapy. Furthermore, methods for measuring cortisol are disparate across studies. We describe the literature reporting cortisol levels in people living with HIV, describe methods to measure cortisol, and explore how this relates to health outcomes. Methods We searched the PubMed database for articles published in the past 20 years regarding HIV and cortisol with >= 50% of participants on antiretroviral therapies. Articles included observational, case-control, cross-sectional, and randomized controlled trials analyzing cortisol by any method. Studies were excluded if abnormal cortisol was due to medications or other infections. Variables were extracted from selected studies and their quality was assessed using the Newcastle-Ottawa Scale. Results In total, 19 articles were selected and included, covering the prevalence of abnormal cortisol (n = 4), exercise (n = 4), metabolic syndrome and/or cardiovascular disease (n = 2), mental health and cognition (n = 9), and sex/gender (n = 6). Cortisol was measured in serum (n = 7), saliva (n = 8), urine (n = 2), and hair (n = 3) specimens. Comparisons between people with and without HIV were inconsistent, with some evidence that people with HIV have increased rates of hypocortisolism. Depression and cognitive decline may be associated with cortisol excess, whereas anxiety and metabolic disease may be related to low cortisol; more data are needed to confirm these relationships. Conclusions Data on cortisol levels in the era of antiretroviral therapy remain sparse. Future studies should include controls without HIV, appropriately timed sample collection, and consideration of sex/gender and psychosocial factors.


  • Open Access

    British Columbia CARMA-CHIWOS Collaboration (BCC3): protocol for a community-collaborative cohort study examining healthy ageing with and for women living with HIV

    by Shayda A Swann, Angela Kaida, Valerie Nicholson, Jason Brophy, Amber R Campbell, Allison Carter, Chelsea Elwood, Tsion Gebremedhen, Rebecca Gormley, Elizabeth M King, et al.

    Introduction: Women living with HIV (WLWH) experience accelerated ageing and an increased risk of age-associated diseases earlier in life, compared with women without HIV. This is likely due to a combination of viral factors, gender differences, hormonal imbalance and psychosocial and structural conditions. This interdisciplinary cohort study aims to understand how biological, clinical and sociostructural determinants of health interact to modulate healthy ageing in WLWH. Methods and analysis: The British Columbia C hildren and Women: A nti R etroviral therapy and M arkers of A ging- C anadian HI V W omen’s Sexual and Reproductive Health Cohort S tudy (CARMA-CHIWOS) Collaboration (BCC3) study will enrol WLWH (n=350) and sociodemographically matched HIV-negative women (n=350) living in British Columbia. A subset of BCC3 participants will be past participants of CARMA, n≥1000 women and children living with and without HIV, 2008–2018 and/or CHIWOS, n=1422 WLWH, 2013–2018. Over two study visits, we will collect biological specimens for virus serologies, hormones and biological markers as well as administer a survey capturing demographic and sociostructural–behavioural factors. Sociodemographics, comorbidities, number and type of chronic/latent viral infections and hormonal irregularities will be compared between the two groups. Their association with biological markers and psychostructural and sociostructural factors will be investigated through multivariable regression and structural equation modelling. Retrospective longitudinal analyses will be conducted on data from past CARMA/CHIWOS participants. As BCC3 aims to follow participants as they age, this protocol will focus on the first study visits. Ethics and dissemination: This study has been approved by the University of British Columbia Children’s and Women’s Research Ethics Board (H19-00896). Results will be shared in peer-reviewed journals, conferences and at community events as well as at www.hivhearme.ca and @HIV_HEAR_me. WLWH are involved in study design, survey creation, participant recruitment, data collection and knowledge translation. A Community Advisory Board will advise the research team throughout the study.


  • Open Access

    Natural HIV-1 Nef Polymorphisms Impair SERINC5 Downregulation Activity

    by Steven W. Jin, Nirmin Alsahafi, Xiaomei T. Kuang, Shayda A. Swann, Mako Toyoda, Heinrich Göttlinger, Bruce D. Walker, Takamasa Ueno, Andrés Finzi, Zabrina L. Brumme, et al.